TiumBio to Present Phase 2a Interim Data Highlighting Differentiated Clinical Profile for Tosposertib(TU2218) plus Pembrolizumab in First-Line R/M HNSCC at ASCO 2026

75.0% Response Rate and Median PFS of 10.9 Months Observed in First-Line Recurrent or Metastatic Head and Neck Cancer(R/M HNSCC) Advancing Tosposertib Toward Next-Stage Development as a Potential Best-in-Class Treatment Option

TiumBio to Present Phase 2a Interim Data Highlighting Differentiated Clinical Profile for Tosposertib(TU2218) plus Pembrolizumab in First-Line R/M HNSCC at ASCO 2026. TiumBio Co., Ltd. (KOSDAQ: 321550), a clinical-stage biopharmaceutical company focused on discovering and developing innovative therapeutics, announced clinical data for Tosposertib (TU2218), an oral dual inhibitor targeting transforming growth factor-beta (TGF-β) and vascular endothelial growth factor (VEGF), in first-line (1L) recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC) at American Society of Clinical Oncology (ASCO) 2026. The data presented during the poster session included the latest results and follow-up data from the Phase 2a trial evaluating the combination of Tosposertib and Keytruda (Pembrolizumab) as. In addition to the 75% response r...